C-5PRZMediwhale
retinal imaging, AI, cardiovascular risk assessment
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
C-5PRZretinal imaging, AI, cardiovascular risk assessment
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Mediwhale retinal imaging, AI, cardiovascular risk assessment
Mediwhale leverages retinal imaging and AI to support early detection, personalized risk assessment, and preventive care for cardiometabolic disease. Its Dr.Noon CVD product is described as a retina-based AI risk prediction solution for future cardiovascular disease risk. The company says its AI products have regulatory approval and reimbursement in Korea and are available in hospitals in Dubai, the UK, and Italy.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Mediwhale — Near-term readout · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: approved. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic